Obesity and inflammation: the linking mechanism and the complications

Mohammed S Ellulu, Ismail Patimah, Huzwah Khaza'ai, Asmah Rahmat, Yehia Abed, Mohammed S Ellulu, Ismail Patimah, Huzwah Khaza'ai, Asmah Rahmat, Yehia Abed

Abstract

Obesity is the accumulation of abnormal or excessive fat that may interfere with the maintenance of an optimal state of health. The excess of macronutrients in the adipose tissues stimulates them to release inflammatory mediators such as tumor necrosis factor α and interleukin 6, and reduces production of adiponectin, predisposing to a pro-inflammatory state and oxidative stress. The increased level of interleukin 6 stimulates the liver to synthesize and secrete C-reactive protein. As a risk factor, inflammation is an imbedded mechanism of developed cardiovascular diseases including coagulation, atherosclerosis, metabolic syndrome, insulin resistance, and diabetes mellitus. It is also associated with development of non-cardiovascular diseases such as psoriasis, depression, cancer, and renal diseases. On the other hand, a reduced level of adiponectin, a significant predictor of cardiovascular mortality, is associated with impaired fasting glucose, leading to type-2 diabetes development, metabolic abnormalities, coronary artery calcification, and stroke. Finally, managing obesity can help reduce the risks of cardiovascular diseases and poor outcome via inhibiting inflammatory mechanisms.

Keywords: C reactive protein; adiponectin; inflammation; interleukin 6; linking mechanism; obesity.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms linking abdominal obesity and metabolic syndrome via inflammatory mediators [24] TNF-α – tumor necrosis factor α, IL-6 – interleukin 6, NO – nitric oxide, ROS – reactive oxygen species, JNK – c-jun N-terminal kinase, IKK – inhibitor of k kinase, PKR – protein kinase R.
Figure 2
Figure 2
Effects of adiponectin on insulin sensitivity and peripheral tissues [114]. Adiponectin regulates energy expenditure centrally, decreases lipogenesis and glucose output in the liver, improves the immune system via anti-inflammatory effects, and regulates lipid metabolism genes in adipocytes

References

    1. Romano M. Inflammation resolution: does the bone marrow have a say? Am J Hematol. 2008;83:435–6.
    1. Feuerstein GZ, Libby P, Mann DL. Inflammation – a new frontier in cardiac disease and therapeutics. In: Feuerstein GZ, Libby P, Mann DL, editors. Inflammation and cardiac diseases. Birkhäuser Basel; 2003. pp. 1–5.
    1. Seki H, Tani Y, Arita M. Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat. 2009;89:126–30.
    1. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29:439–43.
    1. Lafontan M. Fat cells: afferent and efferent messages define new approaches to treat obesity. Annu Rev Pharmacol Toxicol. 2004;45:119–46.
    1. Stępień M, Stępień A, Wlazeł RN, Paradowski M, Banach M, Rysz J. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study. Lipids Health Dis. 2014;13:29.
    1. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A. 2001;98:9824–9.
    1. Stenlof K, Wernstedt I, Fjallman T, Wallenius V, Wallenius K, Jansson JO. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab. 2003;88:4379–83.
    1. Papanicolau DA, Vgontzas AN. Interleukin-6: the endocrine cytokine. J Clin Endocrinol Metab. 2000;85:1331–2.
    1. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–88.
    1. Rahmanian M, Kelishadi R, Qorbani M, et al. Dual burden of body weight among Iranian children and adolescents in 2003 and 2010: the CASPIAN-III study. Arch Med Sci. 2014;10:96–103.
    1. Krzysztoszek J, Wierzejska E, Zielińska A. Obesity. An analysis of epidemiological and prognostic research. Arch Med Sci. 2015;11:24–33.
    1. Curat CA, Miranville A, Sengenès C, et al. From blood monocytes to adipose tissue-resident macrophages induction of diapedesis by human mature adipocytes. Diabetes. 2004;53:1285–92.
    1. Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360:1509–17.
    1. Karastergiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010;318:69–78.
    1. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911–9.
    1. Straub RH, Hense HW, Andus J, Scholmerich J, Riegger AJ, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopause women: a population-based study. J Clin Endocrinol Metab. 2000;85:1340–4.
    1. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56:1010–3.
    1. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.
    1. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am. 2008;37:753–68.
    1. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46:2347–55.
    1. Trayhurn P, Wood I. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347–55.
    1. Zhang S, Liu Q, Wang J, Harnish DC. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem Biophys Res Commun. 2009;379:476–9.
    1. Ellulu MS, Khaza’ai H, Abed Y, Rahmat A, Ismail P, Ranneh Y. Role of fish oil in human health and possible mechanism to reduce the inflammation. Inflammopharmacology. 2015;23:79–89.
    1. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6:399–409.
    1. IllÁn-GÓmez F, GonzÁlvez-Ortega M, Orea-Soler I, et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22:950–5.
    1. Arnardottir ES, Maislin G, Schwab RJ, et al. The interaction of obstructive sleep apnea and obesity on the inflammatory markers C-reactive protein and interleukin-6: the Icelandic Sleep Apnea Cohort. Sleep. 2012;35:921.
    1. Wannamethee SG, Whincup PH, Rumley A, Lowe G. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost. 2007;5:1637–43.
    1. Warnberg J, Moreno LA, Mesana MI, Marcos A The AVENA group. Inflammatory mediators in overweight and obese Spanish adolescents. The AVENA Study. Int J Obes. 2004;28:S59–63.
    1. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/Stat pathway in human malignancies. J Clin Oncol. 2012;30:1005–14.
    1. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:e78.
    1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.
    1. Adar SD, D’Souza J, Mendelsohn-Victor K, et al. Markers of inflammation and coagulation after long-term exposure to coarse particulate matter: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis. Environ Health Perspect. 2015;123:541–8.
    1. Sarvottam K, Yadav RK. Adiponectin, interleukin-6, and endothelin-1 correlate with modifiable cardiometabolic risk factors in overweight/obese men. J Altern Complement Med. 2014;20:419–20.
    1. Chen SJ, Yen CH, Huang YC, Lee BJ, Hsia S, Lin PT. Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome. PLoS One. 2012;7:e45693.
    1. Von Eynatten M, Hamann A, Twardella D, Nawroth P, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidaemia, and heart failure in patients with coronary heart disease. Clin Chem. 2006;52:853–9.
    1. Fernandez-Real JM, Monteserrat M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86:1154–9.
    1. Pradhan A, Manson J, Rifai N, Buring J, Ridker P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;682:327–34.
    1. Ridker PM, Rifai N, Meir J, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–72.
    1. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54–74.
    1. Zhou B, Liu J, Wang Z, Xi T. C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One. 2012;7:e43075.
    1. Ara T, DeClerck Y. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46:1223–31.
    1. Matura LA, Ventetuolo CE, Palevsky HI, et al. Interleukin-6 and tumor necrosis factor-alpha are associated with quality of life-related symptoms in pulmonary arterial hypertension. Ann Am Thorac Soc. 2015;12:370–5.
    1. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol. 2013;164:141–50.
    1. Fujishima S, Watanabe H, Kawaguchi M, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res. 2010;302:499–505.
    1. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8:S3.
    1. Di Cesare PE, Chang E, Preston CF, Liu CJ. Serum interleukin-6 as a marker of periprosthetic infection following total hip and knee arthroplasty. J Bone Joint Surg Am. 2005;87:1921–7.
    1. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005:273–9.
    1. Musselman D, Miller A, Porter M, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158:1252–7.
    1. Wirtz DC, Heller KD, Miltner O, Zilkens KW, Wolff JM. Interleukin-6: a potential inflammatory marker after total joint replacement. Int Orthop. 2000;24:194–6.
    1. Elder JT, Sartor CI, Boman DK, Benrazavi S, Fisher GJ, Pittelkow MR. Interleukin-6 in psoriasis: expression and mitogenicity studies. Arch Dermatol Res. 1992;284:324–32.
    1. Backes JM, Howard PA, Moriarty P. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother. 2004;38:110–8.
    1. Ishii S, Karlamangla A, Bote M, et al. Gender, obesity and repeated elevation of C-reactive protein: data from the CARDIA Cohort. PLoS One. 2012;7:e36062.
    1. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.
    1. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–97.
    1. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005;45:1563–9.
    1. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem. 2003;49:1258–71.
    1. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783–90.
    1. Vadakayil AR, Dandekeri S, Kambil SM, Ali NM. Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol Online J. 2015;6:322–5.
    1. Takahashi H, Iinuma S, Honma M, Iizuka H. Increased serum C-reactive protein level in Japanese patients of psoriasis with cardio- and cerebrovascular disease. J Dermatol. 2014;41:981–5.
    1. Ma A, Pan X, Xing Y, Wu M, Wang Y, Ma C. Elevation of serum CXCL16 level correlates well with atherosclerotic ischemic stroke. Arch Med Sci. 2014;10:47–52.
    1. KöşÜş N, KöşÜş A, Turhan N. Relation between abdominal subcutaneous fat tissue thickness and inflammatory markers during pregnancy. Arch Med Sci. 2014;10:739–45.
    1. Kurtoglu E, Korkmaz H, Akturk E, Yılmaz M, Altas Y, Uckan A. Association of mitral annulus calcification with high-sensitivity C-reactive protein, which is a marker of inflammation. Mediators Inflamm. 2012;2012:606207.
    1. Rajendran K, Devarajan N, Ganesan M, Ragunathan M. Obesity, inflammation and acute myocardial infarction – expression of leptin, IL-6 and high sensitivity-CRP in Chennai based population. Thromb J. 2012;10:13.
    1. Woodard G, Mehta V, Mackey R, et al. C-reactive protein is associated with aortic stiffness in a cohort of African American and white women transitioning through menopause. Menopause. 2011;18:1291–7.
    1. Lee S, Kim IT, Park HB, et al. High-sensitivity C-reactive protein can predict major adverse cardiovascular events in Korean patients with type 2 diabetes. J Kor Med Sci. 2011;26:1322–7.
    1. Kalhan R, Tran BT, Colangelo LA, et al. Systemic inflammation in young adults is associated with abnormal lung function in middle age. PLoS One. 2010;5:e11431.
    1. Den Hertog HM, van Rossum JA, van der Worp HB, et al. C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. J Neurol. 2009;256:2003–8.
    1. Devaraj S, Yun J, Adamson G, Galvez J, Jialal I. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res. 2009;84:479–84.
    1. Cirillo P, Sautin Y, Kanellis J, et al. Systemic inflammation, metabolic syndrome and progressive renal disease. Nephrol Dial Transplant. 2009;24:1384–7.
    1. Hubel C, Powers R, Snaedal S, et al. CRP is elevated 30 years after eclamptic pregnancy. Hypertension. 2008;51:1499–505.
    1. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006;15:381–4.
    1. Erlinger TP, Platz EA, Rifai N, Helzlsouer K. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–90.
    1. Seddon J, Gensler C, Milton R, Klein M, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA. 2004;291:704–10.
    1. Russell AI, Graham DC, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet. 2004;13:137–47.
    1. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945–51.
    1. Stuveling EM, Hillege HL, Bakker S, Gans R, de Jong PE, de Zeeuw D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int. 2003;63:654–61.
    1. Ridker PM. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation. 2003;108:e81–5.
    1. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean M, Haffner S. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25:2016–21.
    1. Mallya RK, De Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol. 1981;9:224–8.
    1. Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to abdominal adiposity. Am J Cardiol. 2010;106:56–61.
    1. Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev. 2013;14:232–44.
    1. Klisic A, Vasiljevic N, Simic T, Djukic T, Maksimovic M, Matic M. Association between C-reactive protein, anthropometric and lipid parameters among healthy normal weight and overweight postmenopause women in Montenegro. Lab Med. 2014;45:12–6.
    1. Dayal D, Jain H, Attri S, Bharti B, Bhalla A. Relationship of high sensitivity C-reactive protein levels to anthropometric and other metabolic parameters in Indian children with simple overweight and obesity. J Clin Diagn Res. 2014;8:PC05.
    1. Kawamoto R, Kusunoki T, Abe M, Kohara K, Miki T. An association between body mass index and high-sensitivity C-reactive protein concentrations is influenced by age in community-dwelling persons. Ann Clin Biochem. 2013;50:457–64.
    1. Ajani UA, Ford E, Mokdad A. Prevalence of high C-reactive protein in persons with serum lipid concentrations within recommended values. Clin Chem. 2004;50:1618–22.
    1. Khand F, Shaikh SS, Ata MA, Shaikh SS. Evaluation of the effect of smoking on complete blood counts, serum C-reactive protein and magnesium levels in healthy adult male smokers. J Pak Med Assoc. 2015;65:59–61.
    1. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.
    1. Swiatkiewicz I, Kozinski M, Magielski P, et al. Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res. 2012;61:725–34.
    1. Van Leeuwen WA, Lehto M, Karisola P, et al. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PLoS One. 2009;4:e4589.
    1. Shivpuri S, Gallo L, Crouse J, Allison M. The association between chronic stress type and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA): does gender make a difference? J Behav Med. 2012;35:74–85.
    1. Kwon YS, Chi SY, Shin HJ, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Kor Med Sci. 2010;25:1487–91.
    1. Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81:687–93.
    1. Rader DJ. Liver X receptor and farnesoid X receptor as therapeutic targets. Am J Cardiol. 2007;100:S15–9.
    1. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–5.
    1. Evans MJ, Mahaney PE, Zhang S, et al. A synthetic farnesoid X receptor agonist protects against diet-induced dyslipidemia. Circulation. 2007;116:II–106.
    1. Li J, Wilson A, Kuruba R, et al. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res. 2008;77:169–77.
    1. Blaschke F, Takata Y, Caglayan E, et al. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ Res. 2006;99:e88–99.
    1. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis. J Biol Chem. 2002;277:37487–91.
    1. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.
    1. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89:2563–8.
    1. Alvarez A, Brodsky JB, Lemmens H, Morton JM. Morbid obesity: peri-operative management. 2nd ed. Cambridge University Press; 2010.
    1. Pischon T, Rimm E. Adiponectin: a promising marker for cardiovascular disease. Clin Chem. 2006;52:797–9.
    1. Oh D, Giaraldi T, Henry R. Adiponectin in health and disease. Diab Obes Metab. 2007;9:282–9.
    1. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671–4.
    1. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580:2917–21.
    1. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol. 2007;292:H1655–63.
    1. Nakamura Y, Shimada K, Fukuda D, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart. 2004;90:528–33.
    1. Ouedraogo R, Wu X, Xu SQ, et al. Adiponectin suppression of highglucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes. 2006;55:1840–6.
    1. Harmancey R, Wilson C, Taegtmeyer H. Adaptation and maladaptation of the heart in obesity. Hypertension. 2008;52:181–7.
    1. Park S, Kim DS, Kwon DY, Yang HJ. Long-term central infusion of adiponectin improves energy and glucose homeostasis by decreasing fat storage and suppressing hepatic gluconeogenesis without changing food intake. J Neuroendocrinol. 2011;23:687–98.
    1. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–7.
    1. Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005;111:747–53.
    1. Turer A, Scherer P. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012;55:2319–26.
    1. Ricci R, Bevilacqua F. The potential role of leptin and adiponectin in obesity: a comparative review. Vet J. 2012;191:292–8.
    1. Stępień M, Stępień A, Wlazeł RN, et al. Predictors of insulin resistance in patients with obesity a pilot study. Angiology. 2014;65:22–30.
    1. Eglit T, Ringmets I, Lember M. Obesity, high-molecular-weight (HMW) adiponectin, and metabolic risk factors: prevalence and gender-specific associations in Estonia. PLoS One. 2013;8:e73273.
    1. Snijder MB, Flyvbjerg A, Stehouwer C, et al. Relationship of adiposity with arterial stiffness as mediated by adiponectin in older men and women: the Hoorn Study. Eur J Endocrinol. 2009;160:387–95.
    1. Dekker JM, Funahashi T, Nijpels G, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab. 2008;93:1489–96.
    1. Jaleel F, Jaleel A, Rahman M, Alam E. Comparison of adiponectin, leptin and blood lipid levels in normal and obese postmenopause women. J Pak Med Assoc. 2006;56:391–4.
    1. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975–81.
    1. Tziakas DN, Chalikias GK, Kaski JC. Epidemiology of the diabetic heart. Coron Artery Dis. 2005;16:S3–10.
    1. Baratta R, Amato S, Degano C, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab. 2004;89:2665–71.
    1. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33:547–94.
    1. Narayan A, Kulkarni S, Kothari R, Deepak T, Kempegowda P. Association between plasma adiponectin and risk of myocardial infarction in Asian Indian patient with diabetes. Br J Med Pract. 2014;7:e729.
    1. Kanhai DA, Kranendonk ME, Uiterwaal C, Graaf Y, Kappelle L, Visseren F. Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obes Rev. 2013;14:555–67.
    1. Kim DH, Kim C, Ding E, Townsend M, Lipsitz L. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62:27–32.
    1. Blaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between adiponectin level, insulin sensitivity, and metabolic syndrome in type 1 diabetic patients. Int J Endocrinol. 2013;2013:535906.
    1. Kim SY, Lee SJ, Park H, et al. Adiponectin is associated with impaired fasting glucose in the non-diabetic population. Epidemiol Health. 2011;33:e2011007.
    1. Ho DY, Cook NR, Britton KA, et al. High-molecular-weight and total adiponectin levels and incident symptomatic peripheral artery disease in women. Circulation. 2011;124:2303–11.
    1. Li S, Shin HJ, Ding EL, van Dam R. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302:179–88.
    1. Greif M, Becker A, von Ziegler F, et al. Pericardial adipose tissue determined by dual source CT is a risk factor for coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:781–6.
    1. Marso SP, Mehta SK, Frutkin A, House JA, McCarary JR, Kullarni KR. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care. 2008;31:989–94.
    1. Qasim A, Mehta NN, Tadesse MG, et al. Adipokines, insulin resistance and coronary artery calcification. J Am Coll Cardiol. 2008;52:231–6.
    1. Hanley AG, Bowden D, Wagenknecht LE, et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab. 2007;92:2665–71.
    1. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab. 2007;92:571–6.
    1. Badawi A, Klip A, Haddad P, et al. Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes. 2010;3:173–86.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren